Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | HPGDS | O60760 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11703369 | 1.00 | HPGD (0.76) | HPGDPTGS1PTGS2ALDH1A1CYP2C9 | |
| SCHEMBL15486632 | 0.91 | HPGD (0.64) | HPGDPTGS1PTGS2ALDH1A1CYP2C9 | |
| (R)-Suprofen SCHEMBL1122667 | 0.86 | PTGS2 (1.00) | HPGDPTGS1PTGS2ALDH1A1CYP2C9 | |
| (S)-Suprofen SCHEMBL5102821 | 0.86 | PTGS2 (1.00) | HPGDPTGS1PTGS2ALDH1A1CYP2C9 | |
| SCHEMBL12286991 | 0.86 | HPGD (0.83) | HPGDPTGS1PTGS2ALDH1A1CYP2C9 | |
| Suprofen SCHEMBL23792 | 0.86 | PTGS2 (1.00) | HPGDPTGS1PTGS2ALDH1A1CYP2C9 | |
| SCHEMBL3805719 | 0.85 | HPGD (0.76) | HPGDPTGS1PTGS2ALDH1A1CYP2C9 | |
| SCHEMBL11706983 | 0.85 | HPGD (0.76) | HPGDPTGS1PTGS2ALDH1A1CYP2C9 | |
| Suprofen SCHEMBL9621599 | 0.85 | PTGS2 (0.97) | HPGDPTGS1PTGS2ALDH1A1CYP2C9 | |
| SCHEMBL13875307 | 0.85 | HPGD (0.76) | HPGDPTGS1PTGS2ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1913011-B1 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS INC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-1789553-B1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8470988-B2 | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8013136-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7893224-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100197899-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A 2-ARYLPROPYL MOIETY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723512-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7632932-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| US-6646003-B2 | Topically administering to the eye of the patient a therapeutically effective amount of flurbiprofen amide derivative and ketorolac amide derivative to treat ophthalmic angiogenesis- related disorder of the posterior segment of eye | ALCON, INC. (CH) | 2003-11-11 | — | — | US | disclosed |
| US-20030049807-A1 | Micro-organism possessing enantioselective and regioselective nitrile hydratase/amidase activities | INSTITUTO BIOCHIMICO ITALIANO GIOVANNI LOREZINI S.P.A. (IT) | 2003-03-13 | — | — | US | disclosed |
| EP-1291435-A2 | A micro-organism possessing enantioselective and regioselective nitrile hydratase/amidase activities | ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. (IT) | 2003-03-12 | — | — | EP | disclosed |
| US-20020183376-A1 | Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac | ALCON, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002078681-A2 | METHOD OF TREATING OCULAR INFLAMMATORY AND ANGIOGENESIS-RELATED DISORDERS USING AN AMIDE DERIVATIVE OF FLUBIPROFEN OR KETOROLAC | ALCON, INC. (CH) | 2002-10-10 | — | — | WO | disclosed |
| US-4064132-A | ANTIINFLAMMATORY AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-12-20 | — | — | US | disclosed |
| US-4060528-A | ANTIINFLAMMATORY | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-11-29 | — | — | US | disclosed |
| US-4035376-A | ESTERS, AMIDES, HYDROXAMIC ACIDS, ANTIINFLAMMATORY | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183376-A1 | Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac | PTGIR, AADAC, PTGS1 | HPGD 81/4885PTGS1 3/4885PTGS2 10/4885 |
| US-20100197899-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A 2-ARYLPROPYL MOIETY | SAAL1, OPRL1, ANXA2 | HPGD 1670/4885PTGS1 143/4885PTGS2 46/4885 |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | DUT, NOP58, DPYD | HPGD 1683/4885PTGS1 3450/4885PTGS2 3642/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | HPGD 2310/4885PTGS1 4228/4885PTGS2 3852/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | HPGD 2709/4885PTGS1 3946/4885PTGS2 4060/4885 |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | HPGD 3995/4885PTGS1 4587/4885PTGS2 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.